Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 21 analyst ratings
Hold
Strong Buy 14%
Buy 33%
Hold 38%
Sell 14%
Strong Sell 0%

Bulls say

ResMed's financial performance indicates a robust outlook, highlighted by an 80 basis point year-over-year increase in operating margin primarily driven by a 230 basis point rise in gross margin, supported by pricing strategies, manufacturing efficiencies, and lower component costs. The company's Americas respiratory sales reached $749 million, reflecting a 12% growth, while the overall respiratory sales in the rest of the world increased by 8%. Furthermore, the anticipated acceleration in wearables, with a significant majority of practitioners expecting an increase in CPAP patients, suggests a favorable future demand landscape for ResMed's products, reinforcing its market position.

Bears say

ResMed's gross margin remained flat sequentially, raising concerns about its financial health amid increasing competitive pressures. The company's organic revenue growth decelerated from 11% in F1Q25 to 10% in F2Q25, with projections suggesting a potential slowdown below 5% in the future due to expected market share losses and headwinds from GLP-1 weight loss drugs. Additionally, risks from Philips' re-entry into the flow generator market and weaker-than-expected margins present significant challenges that could further impact ResMed's earnings and market position.

ResMed (RMD) has been analyzed by 21 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 33% recommend Buy, 38% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 21 analysts, ResMed (RMD) has a Hold consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $178.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $178.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.